Home  >  News
6Sugar_Free_Sweetener.gif
you can get e-magazine links on WhatsApp. Click here
International + Font Resize -

Kineta to extend & expand research pact with Genentech to develop a9/a10 nAchR antagonist to treat chronic pain into phase 1 trials

Seattle
Friday, October 9, 2020, 15:30 Hrs  [IST]

Kineta Chronic Pain, LLC, a subsidiary of Kineta, Inc. announced that the company will extend and expand its research collaboration with Genentech, a member of the Roche Group. With the extension, Kineta will continue development of a9/a10 nicotinic acetylcholine receptor (nAChR) antagonists and will advance KCP506 through phase 1 clinical trials. Kineta will also receive an undisclosed payment from Genentech to extend the research collaboration.

KCP506 is a first-in-class a9a10 nAChR antagonist in development for the treatment of chronic neuropathic pain. Kineta recently received Clinical Trial Application (CTA) approval from the Netherlands to initiate phase 1 trials of KCP506. A single ascending dose and multiple ascending dose study will be conducted in healthy subjects to evaluate the safety, tolerability, and pharmacokinetics of KCP506 and will commence in Q4 2020.

"Our team is excited that Genentech has committed to extending the research collaboration with Kineta as they have been an extremely collaborative partner," said Kineta CEO Shawn Iadonato. "This is an important step in the development of KCP506 and a tremendous milestone achievement for the company."

Kineta initially established a research collaboration and option agreement with Genentech in April 2018. Under the terms of the agreement, Genentech has an option to license assets developed during the research collaboration. If Genentech exercises its option under the agreement, Genentech will be responsible for further development and commercialization. Additionally, Kineta is eligible to receive development and commercialization milestone payments up to $359 million based on achievement of certain predetermined milestones plus high single to low double-digit royalties on sales of certain products resulting from the collaboration.

KCP506 is a novel a9a10 nAChR antagonist in development for the treatment of chronic neuropathic pain. a9a10 nAChR antagonists have demonstrated robust analgesic, anti-neuroinflammatory and neuroprotective effects across multiple preclinical chronic pain models.  KCP506 offers the potential for a disease modifying therapy that may slow or halt the progression of chronic pain. KCP506 may potentially be an effective treatment for many types of chronic neuropathic pain including radiculopathy, chemotherapy-induced peripheral neuropathy and diabetic neuropathy. The global neuropathic pain market was $6.3 billion in 2019 and is expected to reach to $9.9 billion by 2027. Kineta established a strategic partnership in April 2018 with Genentech, a member of the Roche Group. The research collaboration is focused on developing first in class a9a10 nAChR antagonists for the treatment of chronic pain.

Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
truking"
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |